Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Abivax

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax presents third quarter 2024 key financial information
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax presents first-half 2024 financial results
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax Provides Operational and Key Program Update
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024
From Abivax
Via GlobeNewswire
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents
From Abivax
Via GlobeNewswire
Abivax publishes financial reports with the French and U.S. securities regulatory agencies
From Abivax
Via GlobeNewswire
Abivax reports 2023 financial results and operational update
From Abivax
Via GlobeNewswire
Abivax appoints Ana Sharma as Vice President, Global Head of Quality
From Abivax
Via GlobeNewswire
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
From Abivax
Via GlobeNewswire
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
From Abivax
Via GlobeNewswire
Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months
From Abivax
Via GlobeNewswire
Abivax 2024 Financial Communication Calendar
From Abivax
Via GlobeNewswire
Abivax announces the resumption of its liquidity contract
From Abivax
Via GlobeNewswire
Abivax to participate in the Piper Sandler 35th Annual Healthcare Conference
From Abivax
Via GlobeNewswire
Abivax Releases the Results of its June 9, 2022 Ordinary Annual and Extraordinary General Meeting
From ABIVAX
Via AccessWire
Abivax Phase 2a Study Results of Obefazimod (ABX464) in Rheumatoid Arthritis Published in the Journal "Annals of the Rheumatic Diseases" and Selected for Presentation at EULAR 2022
From ABIVAX
Via AccessWire
Abivax Announces Annual Ordinary and Extraordinary General Meeting on June 9, 2022, and the Availability of the Preparatory Documents
From ABIVAX
Via AccessWire
Abivax Publishes Universal Registration Document 2022 'Document d'Enregistrement Universel'
From ABIVAX
Via AccessWire
Abivax Reports Excellent One-Year Efficacy and Safety Data of ABX464 Phase 2b Maintenance Trial in Ulcerative Colitis
From ABIVAX
Via AccessWire
Abivax Reports 2021 Financial Results and Operations Update
From ABIVAX
Via AccessWire
Abivax Reports Promising ABX464 Phase 2a One-Year Maintenance Results in Rheumatoid Arthritis
From ABIVAX
Via AccessWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.